FDA Gives OK for Viracta’s Phase Ib/II Trial of Oral Combo in Epstein-Barr Virus Tumors

The U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a Phase Ib/II trial of Viracta Therapeutics’ all-oral combination regimen in advanced Epstein-Barr Virus-Positive (EBV+) solid tumors. The study will also investigate the oral combination with PD-1 inhibitor pembrolizumab in EBV+ metastatic nasopharyngeal carcinoma (RM-NPC).